X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA GSK PHARMA ELDER PHARMA/
GSK PHARMA
 
P/E (TTM) x -0.2 67.6 - View Chart
P/BV x 0.1 13.6 0.7% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ELDER PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
GSK PHARMA
Mar-18
ELDER PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3802,760 13.8%   
Low Rs1882,040 9.2%   
Sales per share (Unadj.) Rs491.2339.0 144.9%  
Earnings per share (Unadj.) Rs-3.241.4 -7.7%  
Cash flow per share (Unadj.) Rs14.445.9 31.4%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs376.5242.9 155.0%  
Shares outstanding (eoy) m20.5484.70 24.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.67.1 8.2%   
Avg P/E ratio x-89.357.9 -154.0%  
P/CF ratio (eoy) x19.752.3 37.7%  
Price / Book Value ratio x0.89.9 7.6%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m5,833203,280 2.9%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1795,234 41.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08928,715 35.1%  
Other income Rs m257545 47.0%   
Total revenues Rs m10,34629,260 35.4%   
Gross profit Rs m-7925,059 -15.7%  
Depreciation Rs m361380 95.1%   
Interest Rs m2,7562 137,815.0%   
Profit before tax Rs m-3,6535,222 -70.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713178 2,085.8%   
Tax Rs m1251,892 6.6%   
Profit after tax Rs m-653,508 -1.9%  
Gross profit margin %-7.817.6 -44.6%  
Effective tax rate %-3.436.2 -9.5%   
Net profit margin %-0.612.2 -5.3%  
BALANCE SHEET DATA
Current assets Rs m9,24021,815 42.4%   
Current liabilities Rs m9,99815,999 62.5%   
Net working cap to sales %-7.520.3 -37.1%  
Current ratio x0.91.4 67.8%  
Inventory Days Days4664 72.8%  
Debtors Days Days6019 320.8%  
Net fixed assets Rs m10,12412,475 81.2%   
Share capital Rs m206847 24.3%   
"Free" reserves Rs m5,58219,726 28.3%   
Net worth Rs m7,73420,573 37.6%   
Long term debt Rs m4,8896 81,483.3%   
Total assets Rs m22,88239,475 58.0%  
Interest coverage x-0.32,612.0 -0.0%   
Debt to equity ratio x0.60 216,768.6%  
Sales to assets ratio x0.40.7 60.6%   
Return on assets %11.88.9 132.3%  
Return on equity %-0.817.1 -5.0%  
Return on capital %22.326.2 85.0%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m307564 54.4%   
Fx outflow Rs m1257,429 1.7%   
Net fx Rs m181-6,865 -2.6%   
CASH FLOW
From Operations Rs m11,7544,728 248.6%  
From Investments Rs m-561-1,042 53.8%  
From Financial Activity Rs m-6,762-3,066 220.5%  
Net Cashflow Rs m4,432620 715.1%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 7.5 10.2 73.5%  
FIIs % 16.8 23.8 70.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 15.4 234.4%  
Shareholders   16,479 102,036 16.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS